CSL has agreed to pay Alentis Therapeutics US$355 million upfront in an exclusive deal to jointly develop and promote lixudebart, an experimental antibody that could become the first in a new class of treatments for people with rare kidney and liver diseases. …
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News